Tyrosine kinase inhibitors: the first decade (Q37738539)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2010

edit

Language	Label	Description	Also known as
English	Tyrosine kinase inhibitors: the first decade	scientific article published on April 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Tyrosine kinase inhibitors: the first decade (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

author

Jorge Eduardo Cortes

series ordinal

3

object named as

Jorge Cortes

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

author name string

Meetu Agrawal

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

Ravin J Garg

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

Alfonso Quintás-Cardama

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

publication date

1 April 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

published in

Current hematologic malignancy reports

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

volume

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

page(s)

70-80

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

cites work

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia: molecular monitoring in clinical practice

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to imatinib mesylate in chronic myeloid leukaemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flying under the radar: the new wave of BCR-ABL inhibitors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20425399

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11899-010-0045-Y

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

PubMed publication ID

20425399

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20425399

retrieved

22 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37738539&oldid=2200901371"